| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | FibroBiologics reports Q3 results | 1 | Seeking Alpha | ||
| 12.11. | RedChip Companies, Inc.: Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications | 248 | ACCESS Newswire | Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblastsManagement to discuss the ongoing Phase... ► Artikel lesen | |
| FIBROBIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 19.10. | FibroBiologics presents data on disc disease treatment approach | 1 | Investing.com | ||
| 14.10. | FibroBiologics receives Australian patent acceptance for disc treatment | 2 | Investing.com | ||
| 14.10. | FibroBiologics, Inc.: FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs | 306 | PR Newswire | Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and... ► Artikel lesen | |
| 08.10. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.10. | FibroBiologics, Inc.: FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body | 237 | PR Newswire | New approach proposes an alternative to repeated injections
HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage... ► Artikel lesen | |
| 07.10. | EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections | 1 | Benzinga.com | ||
| 02.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | 2.876 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| 29.09. | FibroBiologics erhält europäisches Patent für Fibroblasten-Therapie | 4 | Investing.com Deutsch | ||
| 25.09. | RedChip Companies, Inc.: Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 639 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip... ► Artikel lesen | |
| 17.09. | FibroBiologics CSO invests $500,000 in private placement | 1 | Investing.com | ||
| 15.09. | FibroBiologics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | RedChip Companies, Inc.: Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications | 301 | ACCESS Newswire | Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblastsManagement to discuss the ongoing Phase... ► Artikel lesen | |
| 26.08. | FibroBiologics, Inc.: FibroBiologics Regains Compliance with Nasdaq Trading Rules | 225 | PR Newswire | HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+... ► Artikel lesen | |
| 24.08. | FibroBiologics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.08. | FibroBiologics appoints Leigh Steinberg to board | 3 | Investing.com | ||
| 20.08. | FibroBiologics receives Australian patent for disc disease therapy | 1 | Investing.com | ||
| 18.08. | FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment | 1 | Benzinga.com | ||
| 18.08. | FibroBiologics meldet erfolgreiche Knorpelreparatur in Tierstudie | 3 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,60 | -0,07 % | Option auf Zeitgewinn: BioNTech investiert Millionen in möglichen Zulassungsvorsprung | Mit einem Prüfungsgutschein will BioNTech die Entscheidung der US-Arzneimittelbehörde über ein Krebsmedikament um rund vier Monate vorziehen. Damit wären frühere Umsätze möglich, doch Studienrückschläge... ► Artikel lesen | |
| MODERNA | 179,14 | -4,73 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| NOVAVAX | 7,180 | -0,69 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| BIOFRONTERA | 2,820 | -3,75 % | Biofrontera AG: Liquidität unter Druck - was jetzt zählt | ||
| NANOREPRO | 1,395 | +1,09 % | NanoRepro nach starkem H1-Bericht: Diese Marke entscheidet jetzt | ||
| VIVOSIM LABS | 0,122 | +1,58 % | VivoSim presents liver toxicity detection data at ACT meeting | ||
| INOVIO PHARMACEUTICALS | 1,471 | -1,01 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| CLINUVEL | 4,350 | -1,72 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| INFLARX | 1,026 | -2,93 % | InflaRx im Check: Izicopan rückt vor, der Chart bleibt unter Druck | ||
| INTELLIA THERAPEUTICS | 8,880 | 0,00 % | Intellia auf der Jefferies Global Healthcare Conference: Marktstart und Pipeline im Fokus | ||
| DEFENCE THERAPEUTICS | 0,171 | -2,57 % | Defence Therapeutics Inc.: Defence Therapeutics Invites Shareholders to Its December 10, 2026, Annual General Meeting and 2027 Strategic Update | Montreal, Quebec--(Newsfile Corp. - November 16, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 1,675 | +0,90 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,694 | -1,96 % | BioCryst presents real-world data on ORLADEYO at ACAAI meeting | ||
| KUROS BIOSCIENCES | 21,000 | +0,19 % | Kuros Biosciences: Höhere Prognose - der Rebound bekommt Rückenwind | ||
| ABIVAX | 76,75 | +2,20 % | EQS-News: ABIVAX: Abivax to Participate in Upcoming Fall Investor Conferences | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Participate in Upcoming Fall Investor Conferences
02.11.2026 / 22:05 CET/CEST
The issuer is solely responsible for... ► Artikel lesen |